Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
/ 4 items
#ABUS↓
Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
Arbutus vs. Moderna Patent Case Heads to Jury Trial
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.
Arbutus Loses Key European Patent in Moderna Dispute
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.